论文部分内容阅读
作者对美国 Anderson 医院325例初始成人急性白血病患者作诱导缓解治疗,其中245例(75%)为AML(急非淋),其中急粒182例,粒-单35例,急单10例,早幼粒13例,红白血病5例;53例(16%)为急淋或淋巴瘤合并白血病;其余27例(8%)为未能分型的急性白血病。病人年龄中位数为48岁(15～83)。治疗的基础方案由长春新碱、强的松、阿糖胞苷、柔毛霉素加免疫治疗组成。达到完全缓解的标准是:骨髓检查正常,原始细胞少于5%,血中没有原始
The authors treated 325 patients with initial adult acute leukemia at the Anderson Hospital in the United States for induction of remission. Of these, 245 (75%) were AML (emergency non-lymphocytic), among which 182 acute granules, 35 mononuclear cells, and 10 urgent ones. There were 13 cases of granules and 5 cases of erythroleukemia; 53 cases (16%) were acute leukemia or lymphoma with leukemia; the remaining 27 cases (8%) were unclassifiable acute leukemia. The median age of the patients was 48 years (15-83). The basic protocol for treatment consists of vincristine, prednisone, cytarabine, and daunorubicin plus immunotherapy. The criteria for achieving complete remission are: normal bone marrow examination, less than 5% of primitive cells, no original blood